Types segmentation differentiates the class hierarchy by pharmacologic target and, by extension, revenue yield. Proton-pump inhibitors dominate value, generating more than 60 % of global sales despite widespread generics; differentiation rests on modified-release formulations (e.g., dexlansoprazole MR) and fixed-dose combinations that defend margin. H2-receptor antagonists, once standard, now contribute <10 % revenue because OTC commoditization and tolerance issues shift prescriptions to PPIs, although injectable famotidine retains ICU utility. Antacids claim c. 15 %, overwhelmingly from OTC aluminum-magnesium or calcium carbonate liquids; growth is volume-led but price-capped, serving breakthrough symptoms rather than maintenance. Prostaglandin analogs (e.g., misoprostol) occupy <2 %, restricted to NSAID-gastropathy prophylaxis in high-risk elderly cohorts, constrained by dosing complexity and side-effect profile. Finally, potassium-competitive acid blockers (P-CABs) such as vonoprazan are emerging, capturing early adoption and premium pricing in Asia–Pacific; their share is presently <5 % yet forecast to reshape market taxonomy as chronic-use evidence accrues. Each subtype thus delineates a distinct profit and volume stratum within the Antiulcer Agents and Acid Suppressants market.
